Index S&P 500
P/E -
EPS (ttm) -7.26
Insider Own 8.54%
Shs Outstand 390.73M
Perf Week 2.63%
Market Cap 16.82B
Forward P/E -
EPS next Y -4.67
Insider Trans -0.07%
Shs Float 357.38M
Perf Month 9.39%
Enterprise Value 12.29B
PEG -
EPS next Q -2.04
Inst Own 73.85%
Short Float 20.01%
Perf Quarter 72.50%
Income -2.82B
P/S 8.65
EPS this Y 9.31%
Inst Trans 12.72%
Short Ratio 6.12
Perf Half Y 53.66%
Sales 1.94B
P/B 1.80
EPS next Y 29.04%
ROA -21.31%
Short Interest 71.51M
Perf YTD 46.00%
Book/sh 23.86
P/C 2.90
EPS next 5Y 25.64%
ROE -28.87%
52W High 55.20 -22.00%
Perf Year 30.51%
Cash/sh 14.84
P/FCF -
EPS past 3/5Y - -29.93%
ROIC -28.47%
52W Low 22.28 93.25%
Perf 3Y -74.16%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y -53.32% 19.33%
Gross Margin 55.35%
Volatility 7.83% 7.70%
Perf 5Y -75.64%
Dividend TTM -
EV/Sales 6.32
EPS Y/Y TTM -38.95%
Oper. Margin -158.13%
ATR (14) 3.22
Perf 10Y -
Dividend Ex-Date -
Quick Ratio 3.22
Sales Y/Y TTM -39.93%
Profit Margin -145.16%
RSI (14) 56.02
Recom 2.96
Dividend Gr. 3/5Y - -
Current Ratio 3.29
EPS Q/Q 27.57%
SMA20 -2.40%
Beta 1.34
Target Price 40.26
Payout -
Debt/Eq 0.15
Sales Q/Q -29.81%
SMA50 16.05%
Rel Volume 0.88
Prev Close 42.23
Employees 5800
LT Debt/Eq 0.15
Earnings Feb 13 BMO
SMA200 46.32%
Avg Volume 11.68M
Price 43.06
IPO Dec 07, 2018
Option/Short Yes / Yes
EPS/Sales Surpr. 17.07% 6.75%
Trades
Volume 4,489,040
Change 1.95%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-28-26 Resumed
Barclays
Equal Weight
$25
Jan-07-26 Resumed
UBS
Neutral
$34
Dec-12-25 Initiated
Jefferies
Hold
$30
Mar-13-25 Initiated
Citigroup
Neutral
$40
Feb-18-25 Downgrade
Barclays
Overweight → Equal Weight
$111 → $45
Jan-29-25 Downgrade
Goldman
Buy → Neutral
$99 → $51
Dec-18-24 Downgrade
Argus
Buy → Hold
Dec-10-24 Resumed
BofA Securities
Underperform
$41
Nov-19-24 Initiated
Berenberg
Hold
$42
Nov-18-24 Upgrade
HSBC Securities
Hold → Buy
$58
Nov-15-24 Initiated
Wolfe Research
Underperform
$40
Oct-17-24 Initiated
Bernstein
Mkt Perform
$55
Sep-13-24 Downgrade
Oppenheimer
Outperform → Perform
Sep-13-24 Downgrade
JP Morgan
Neutral → Underweight
$88 → $70
Sep-13-24 Downgrade
Jefferies
Buy → Hold
$120 → $65
Aug-28-24 Upgrade
HSBC Securities
Reduce → Hold
$82
Aug-07-24 Upgrade
Deutsche Bank
Sell → Hold
$85 → $80
Aug-05-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$125 → $90
Feb-26-24 Downgrade
HSBC Securities
Hold → Reduce
$75 → $86
Jan-02-24 Upgrade
Oppenheimer
Perform → Outperform
$142
Show Previous Ratings
Today 10:42AM
07:00AM
Feb-16-26 07:48AM
Feb-14-26 12:31AM
Feb-13-26 05:29PM
(Morningstar Research) +5.29%
05:12PM
Loading…
05:12PM
(The Wall Street Journal)
05:03PM
(The Wall Street Journal)
04:51PM
04:20PM
04:15PM
04:02PM
03:51PM
03:37PM
03:09PM
02:51PM
02:16PM
Loading…
02:16PM
02:13PM
(The Wall Street Journal)
02:01PM
12:03PM
11:38AM
11:17AM
10:59AM
10:49AM
10:47AM
10:35AM
10:27AM
10:01AM
09:42AM
(The Wall Street Journal)
09:14AM
(Investor's Business Daily)
09:03AM
(The Wall Street Journal)
08:20AM
Loading…
08:20AM
08:20AM
07:56AM
(The Wall Street Journal)
07:42AM
07:29AM
07:15AM
(Associated Press Finance)
07:13AM
07:12AM
07:11AM
07:00AM
05:54AM
Feb-12-26 07:55PM
07:00PM
06:48PM
06:48PM
06:48PM
06:48PM
06:48PM
12:40PM
(The Wall Street Journal)
10:46AM
08:11AM
08:11AM
07:27AM
06:40AM
03:09AM
(The Wall Street Journal)
Feb-11-26 10:01PM
09:23PM
(The Wall Street Journal)
07:28PM
06:20PM
(The Wall Street Journal)
04:45PM
04:36PM
04:36PM
04:35PM
04:05PM
(Investor's Business Daily)
03:13PM
02:57PM
01:33PM
(Pharmaceutical Technology)
01:00PM
12:29PM
12:27PM
(The Wall Street Journal)
11:46AM
(Pharmaceutical Technology)
10:45AM
10:44AM
10:00AM
(The Wall Street Journal)
09:44AM
08:24AM
08:11AM
07:05AM
06:44AM
06:18AM
06:18AM
06:01AM
05:37AM
05:21AM
04:33AM
03:38AM
(The Wall Street Journal)
01:49AM
Feb-10-26 11:24PM
(Associated Press Finance)
07:14PM
(The Wall Street Journal)
06:04PM
(Investor's Business Daily)
05:02PM
05:02PM
02:03PM
12:26PM
11:01AM
10:45AM
08:15AM
07:00AM
06:41AM
Feb-09-26 05:45PM
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
AFEYAN NOUBAR Director Dec 11 '25 Option Exercise 10.90 23,853 259,998 27,777 Dec 15 09:00 AM AFEYAN NOUBAR Director Dec 11 '25 Sale 29.48 23,853 703,306 3,924 Dec 15 09:00 AM Bancel Stephane Chief Executive Officer Dec 11 '25 Option Exercise 10.90 688,073 7,499,996 6,181,970 Dec 15 08:59 AM Flagship Pioneering Inc. Affiliate Dec 11 '25 Proposed Sale 29.49 23,853 703,306 Dec 11 04:30 PM Hussain Abbas Director Dec 09 '25 Sale 27.60 504 13,910 1,515 Dec 11 04:16 PM Hussain Abbas Director Dec 09 '25 Proposed Sale 27.60 504 13,910 Dec 09 10:26 AM Hussain Abbas Director Jun 11 '25 Sale 28.00 312 8,736 580 Jun 12 04:22 PM Hussain Abbas Director Jun 11 '25 Proposed Sale 28.00 312 8,736 Jun 11 10:06 AM Bancel Stephane Chief Executive Officer Mar 03 '25 Buy 31.22 160,314 5,004,318 9,210,686 Mar 04 04:27 PM SAGAN PAUL Director Mar 03 '25 Buy 31.76 31,620 1,004,251 312,027 Mar 04 04:24 PM